📊 TCRX Key Takeaways
Is TScan Therapeutics, Inc. (TCRX) a Good Investment?
TScan Therapeutics exhibits a classic pre-commercial biotech profile with severe cash burn of $135.3M annually against minimal $10.3M revenue, creating an estimated 1-2 year cash runway despite strong balance sheet reserves. While 266.7% revenue growth is notable, the company cannot achieve profitability at scale without dramatic expense reduction or massive revenue acceleration, and faces material execution and financing risk.
Why Buy TScan Therapeutics, Inc. Stock? TCRX Key Strengths
- Excellent balance sheet with $152.4M cash reserves and low leverage (0.26x debt/equity)
- Strong revenue growth of 266.7% year-over-year demonstrates market traction
- Outstanding liquidity with 8.41x current ratio provides near-term financial flexibility
TCRX Stock Risks: TScan Therapeutics, Inc. Investment Risks
- Unsustainable cash burn of $135.3M annually with only 1-2 years of runway at current burn rates
- Severe operating losses with -1315.4% operating margin and -1256.8% net margin indicate business model not yet viable
- Negative operating and free cash flow of -$135.3M and -$139.7M respectively show the company cannot sustain operations from business activities
- Gross margin data unavailable; inability to assess underlying product profitability at unit level
Key Metrics to Watch
- Quarterly cash burn rate trend and updated cash runway estimate
- Revenue growth sustainability and path to gross profitability by product line
- Operating expense reduction progress relative to revenue scaling
- Clinical trial milestones and regulatory progress for pipeline advancement
- Financing activities and capital raise announcements
TScan Therapeutics, Inc. (TCRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.41x current ratio provides a solid financial cushion.
TCRX Profit Margin, ROE & Profitability Analysis
TCRX vs Healthcare Sector: How TScan Therapeutics, Inc. Compares
How TScan Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is TScan Therapeutics, Inc. Stock Overvalued? TCRX Valuation Analysis 2026
Based on fundamental analysis, TScan Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
TScan Therapeutics, Inc. Balance Sheet: TCRX Debt, Cash & Liquidity
TCRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: TScan Therapeutics, Inc.'s revenue has shown modest growth of 2% over the 5-year period. The most recent EPS of $-1.14 indicates the company is currently unprofitable.
TCRX Revenue Growth, EPS Growth & YoY Performance
TCRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.0M | -$29.9M | $-0.25 |
| Q2 2025 | $536.0K | -$31.7M | $-0.28 |
| Q1 2025 | $566.0K | -$30.1M | $-0.26 |
| Q3 2024 | $1.0M | -$23.0M | $-0.24 |
| Q2 2024 | $536.0K | -$24.0M | $-0.28 |
| Q1 2024 | $566.0K | -$22.6M | $-0.32 |
| Q3 2023 | $3.4M | -$16.2M | $-0.24 |
| Q2 2023 | $3.1M | -$15.1M | $-0.51 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
TScan Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
TCRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for TScan Therapeutics, Inc. (CIK: 0001783328)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TCRX
What is the AI rating for TCRX?
TScan Therapeutics, Inc. (TCRX) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TCRX's key strengths?
Claude: Excellent balance sheet with $152.4M cash reserves and low leverage (0.26x debt/equity). Strong revenue growth of 266.7% year-over-year demonstrates market traction.
What are the risks of investing in TCRX?
Claude: Unsustainable cash burn of $135.3M annually with only 1-2 years of runway at current burn rates. Severe operating losses with -1315.4% operating margin and -1256.8% net margin indicate business model not yet viable.
What is TCRX's revenue and growth?
TScan Therapeutics, Inc. reported revenue of $10.3M.
Does TCRX pay dividends?
TScan Therapeutics, Inc. does not currently pay dividends.
Where can I find TCRX SEC filings?
Official SEC filings for TScan Therapeutics, Inc. (CIK: 0001783328) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TCRX's EPS?
TScan Therapeutics, Inc. has a diluted EPS of $-1.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TCRX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, TScan Therapeutics, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TCRX stock overvalued or undervalued?
Valuation metrics for TCRX: ROE of -105.4% (sector avg: 15%), net margin of -1,256.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TCRX stock in 2026?
Our dual AI analysis gives TScan Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TCRX's free cash flow?
TScan Therapeutics, Inc.'s operating cash flow is $-135.3M, with capital expenditures of $4.4M. FCF margin is -1,353.3%.
How does TCRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,256.8% (avg: 12%), ROE -105.4% (avg: 15%), current ratio 8.41 (avg: 2).